_inhibitor-by-ed-carter.jpg "Inhibitor by Ed Carter from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 93 sec
✓ Published: 09-Jun-2014
✓ Published: 09-Jun-2014
Description:
Researchers at the Northern Institute for Cancer Research (NICR) have played a central role in the development of PARP Inhibitors – a targeted treatment that kills cancer cells, while leaving healthy cells relatively unscathed. The first cancer patient in the world to be given this new type of drug was treated in Newcastle in 2003.nnIn response to this incredible research, Ed Carter has worked closely with the NICR team over a number of months to create “Inhibitor”.nnVisually, a series of
Researchers at the Northern Institute for Cancer Research (NICR) have played a central role in the development of PARP Inhibitors – a targeted treatment that kills cancer cells, while leaving healthy cells relatively unscathed. The first cancer patient in the world to be given this new type of drug was treated in Newcastle in 2003.nnIn response to this incredible research, Ed Carter has worked closely with the NICR team over a number of months to create “Inhibitor”.nnVisually, a series of
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_stories-of-innovation-preact.webp "Historically, more than 75% of ovarian cancers would eventually recur, at which point they are not curable. But recent FDA approvals for a new class of oral drugs called parp inhibitors have resulted in significantly improved survival for newly diagnosed ovarian cancer patients.nnHowever, the effectiveness of these treatments is dependent on genetic and tumor mutations. A complex process of multiple genetic and tumor tests, each of which can take weeks to complete, must be completed within fou")
_petra-next-generation-parp1-selective-inhibitor-azd5305-in-patients-with-brca1-2-palb2-or-rad51c-d-mutations.webp "Dr Timothy Yap speaks to ecancer about the PETRA trial that he presented at the AACR 2022 meeting. The trial was a first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations.nnHe reports that the results showed that AZD5305 successfully improved safety and showed promising clinical activity.nnDr Yap believes that this is proof of concept in the clinic for this innovative strategy and that expansion trials ar")
⏲ 2 min 70 sec ✓ 11-Apr-2022
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.webp "Dr Neal Shore speaks to Prof Karim Fizazi about the changing landscape of treatments for prostate cancer, discussing immunotherapies, PARP inhibitors and PSMA testing as future targets and treatments.nnDr Fizazi highlights that anti-PD1 treatment (pembrolizumab) may provide benefit for metastatic castration resistant patients following antiandrogen treatment (5 of the 28 patients in the trial had a PSA decline of50%). nnTrials building on immune checkpoint therapies with novel combinations to")
_anthony-d-elias-md-on-triple-negative-breast-cancer-parp-inhibitors-in-the-current-treatment-landscape.webp "Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews new NCCN recommendations for PARP inhibitor therapy in TNBC and the implications of the now-approved olaparib for gBRCA-mutant breast cancer.")
⏲ 2 min 25 sec ✓ 24-Mar-2018
_comparing-parp-inhibitors.webp "Dr Leo speaks with ecancer about results from a head-to-head comparison of five PARP inhibitors. nnHaving compared the approvals, mechanisms and doses of olaparib, veliparib, rucaparib, niraparib and talazoparib, Dr Leo highlights the potential for predicting responses and assessing novel PARP inhibitors.nnFor more on PARP inhibitors, watch our interview with Dr Mark O’Connor here.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.nnhttps://ecancer.org/acc")
_profound-parp-inhibitor-olaparib-compared-with-new-hormonal-agents-in-advanced-castration-resistant-prostate-cancer.webp "Prof Maha Hussain speaks to ecancer at ESMO 2019 in Barcelona about data from the PROfound trial comparing the PARP inhibitor olaparib with new hormonal agents in advanced castration resistant prostate cancer.nnShe reports that in cohort A (patients with BRCA1, BRCA2 or ATM genes) progression free survival was over double in favour of the olaparib and in the overall population of cohort A and cohort B (alterations in other genes involved in DNA repair) there were similar trends.nnProf Hussain be")
⏲ 3 min 98 sec ✓ 30-Sep-2019
_the-role-of-parp-inhibition-in-clinical-practice-a-look-inside-the-e-learning.webp "Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR. The e-learning is designed to support you in selecting the appropriate treatment strategy with PARP inhibitors in the appropriate patient population and to provide the best possible patient care.")
⏲ 70 sec ✓ 25-Sep-2019
_metastatic-granulosa-cell-tumours-and-parp-inhibitors.webp "Prof Ray-Coquard speaks with ecancer about the importance of initial diagnosis and molecular analysis in management of granulosa cell type ovarian cancers.nnShe also discusses clinical trials in this indication, including an upcoming presentation at ESMO 2018 on the first randomised trial for patients on weekly paclitaxel. nnProf Ray-Coquard also discusses the use of PARP inhibitors with antiangeogenic factors to treat ovarian cancers.")
_stories-of-innovation-preact.jpg)
_petra-next-generation-parp1-selective-inhibitor-azd5305-in-patients-with-brca1-2-palb2-or-rad51c-d-mutations.jpg)
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.jpg)
_anthony-d-elias-md-on-triple-negative-breast-cancer-parp-inhibitors-in-the-current-treatment-landscape.jpg)
_comparing-parp-inhibitors.jpg)
_profound-parp-inhibitor-olaparib-compared-with-new-hormonal-agents-in-advanced-castration-resistant-prostate-cancer.jpg)
_the-role-of-parp-inhibition-in-clinical-practice-a-look-inside-the-e-learning.jpg)
_metastatic-granulosa-cell-tumours-and-parp-inhibitors.jpg)
![[+]](/images/menu.gif){kind=small}